2Giugliano D, Standl E, Vilsboll T, et al. Is the current therapeutic ar- mamentarium in diabetes enough to control the epidemic and its conse- quences? What are the current shortcomings? [ J ]. Acta Diabetol, 2009, 46(3) : 173 -181.
3Nauck M A. Unraveling the science of incretin biology [ J]. Eur J In- tern Med, 2009, 20( Suppl 2) : S303 -S308.
4Gupta N A, Mells J, Dunham R M, et al. Glucagon-like peptide-I re- ceptor is present on human hepatocytes and has a direct role in decrea- sing hepatic steatosis in vitro by modulating elements of the insulin sig- naling pathway [J]. Hepatology, 2010, 51 (5): 1584- 1592.
5Nathan D M, Buse J B, Davidson M B, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initia- tion and adjustment of therapy : a consensus statement of the American Diabetes Association and the European Association for the Study of Dia- betes [J]. Diabetes Care, 2009, 32( 1 ) : 193 -203.
6Eng J, Kleinman W A, Singh L, et al. Isolation and characterization of exendin-.4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas I J]. J Biol Chem, 1992, 267( 11 ): 7402-7405.
7Boulton D, Tang A, Patel C, et al. Pharmaeokinetics of the dipeptidyl peptidase-4 inhibitor saxagliptin in subjects with renal impairment [ J]. Endocr Abstr, 2009, 20: 357.
8Yu Z, Jin T. New insights into the role of cAMP in the production and function of the incretin hormone glucagon-like peptide-1 ( GLP-1 ) [ J].Cell Signal, 2010, 22(1) : 1 -8.
9Fehse F, Trautmann M, Hoist J J, et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes [ J]. J Clin Endocrinol Metab, 2005,90 (11) : 5991 -5997.
10Buse J B, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes : a 26-week randomised, par- allel-group, multinational, open-label trial ( LEAD-6 ) [ J ]. Lancet, 2009, 374(9683): 39-47.
